Not For Ophthalmic Use

DESCRIPTION
Each gram of Psorcon E Emollient Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is: 6α,9-difluoro - 11β,17,21-trihydroxy - 16β-methyl-pregna-1,4-diene-3,20-dione 17,21-diacetate. The structural formula is represented below:

Psorcon E Emollient Ointment contains diflorasone diacetate in an emollient, occlusive base consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

CLINICAL PHARMACOLOGY
Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION.) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
INDICATIONS AND USAGE
Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

CONTRAINDICATIONS
Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS
General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See PRECAUTIONS: Pediatric Use.) If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on an infant or child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests: The following tests may be helpful in evaluating the HPA axis suppression:
   Urinary free cortisol test
   ACTH stimulation test

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.
Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

**Pregnancy Category C:** Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

**Nursing Mothers:** It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

**Pediatric Use:** Safety and effectiveness of *Psorcon* E (diflorasone diacetate ointment) in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA-axis suppression when they are treated with topical corticosteroids. They are, therefore, also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in pediatric patients.

HPA axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

**ADVERSE REACTIONS**

The following local adverse reactions have been reported with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

1. Burning
2. Itching
3. Irritation
4. Dryness
5. Folliculitis
6. Hypertrichosis
7. Acneiform eruptions
8. Hyperpigmentation
9. Perioral dermatitis
10. Allergic contact dermatitis
11. Maceration of the skin
12. Secondary infection
13. Skin atrophy
14. Striae
15. Miliaria

**OVERDOSAGE**

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See **PRECAUTIONS**.)

**DOSAGE AND ADMINISTRATION**

Topical corticosteroids should be applied to the affected area as a thin film from one to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.

**HOW SUPPLIED**

*Psorcon* E Emollient Ointment is available as follows:

<table>
<thead>
<tr>
<th>Size</th>
<th>NDC Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 gram tube</td>
<td>0066–0275–17</td>
</tr>
<tr>
<td>30 gram tube</td>
<td>0066–0275–31</td>
</tr>
<tr>
<td>60 gram tube</td>
<td>0066–0275–60</td>
</tr>
</tbody>
</table>

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

Prescribing Information as of December 2001.

Rx only

Manufactured for Dermik Laboratories, Inc.

Bertwyn, PA USA 60112

By Pharmacia & Upjohn Company
A subsidiary of Pharmacia Corporation
Kalamazoo, MI, USA 49001

Revised December 2001

817 503 005

50005610 691694
NDA 17-994

diflorasone diacetate ointment 0.05%

15 Gram Tube
Code 817 461 000

PSORCON<sup>®</sup> emollient ointment
(diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

DIRECTIONS AND PRECAUTIONS: For complete product information, see package insert. For external use only. Not for ophthalmic use.

Keep out of the reach of children. Keep tightly closed.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of propylene glycol, 1,4-dioxyan-2-yl acetate, stearyl alcohol and white petrolatum.

Manufactured by:
DermLab Laboratories, Inc.
A Woldyra Patentee, Inc.

By: Pharmos & Upjohn Company
Davidsburg, SC 29043

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

817 461 000

DermLab Laboratories, Inc.

Code Date and
Custom No. 915160
Tel: 911846
FOR COMPLETE PRODUCT INFORMATION SEE PACKAGE INSERT.

AVGAGE DOSAGE AND INDICATIONS: See package insert.

For external use only. Not for opthalmic use. Keep out of the reach of children.

617 485 000

NET WT 15 Grams TOPOICAL NDC 0066-0276-17

PSORCON® emollient ointment (diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypolyene 15-ethyl ether, stearyl acid, lanolin alcohol and white petrolatum.

Store at controlled room temperature, 20° to 25° C (68° to 77° F) (see USP).

DERMIX LABORATORIES INC.

Manufactured for DERMIX Laboratories, Inc.
A Rhône-Poulenc Rorer Company, Collingdale, PA USA 19023
By Pharmacia & Upjohn Company, Kalamazoo, MI USA 49001

NET WT 15 Grams TOPOICAL NDC 0066-0276-17

PSORCON® emollient ointment (diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.
NDA 17-994

diflorasone diacetate ointment 0.05%

30 Gram Tube
Code 817 462 000

PSORCON®

emollient ointment
(diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

DIRECTIONS AND INSTRUCTIONS: For complete product information, see package insert.
For external use only. Not for ophthalmic use.
Keep out of the reach of children. Keep tightly closed.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyethylene 15-stearyl ether, stearyl alcohol, and white petrolatum.

Manufactured by
Dermik Laboratories, Inc.
A Schering-Plough Research Corporation
Collegeville, PA 19426

by Plimsoll & Upjohn Company
Kalamazoo, MI USA 49001

Store at controlled room temperature, 20° to 25°C (68°F to 77°F) [see USP]

817 462 000

DERMIK LABORATORIES, INC.
Dedicated to Dermatology™

Exp. Date and
Composition vary
W/1123
FOR COMPLETE PRODUCT INFORMATION SEE PACKAGE INSERT.
AVERAGE DOSAGE AND INDICATIONS: See package insert. Literature available to physicians on request.
For external use only. Not for ophthalmic use. Keep out of the reach of children.

817 484 000

NET WT 30 GRAMS   TOPICAL    NDC 0066-0275-31

PSORCON® emollient ointment
(diflorsone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

DESCRIPTION: Each gram contains 0.6 mg of diflorsone diacetate in a vehicle consisting of polysorbate 80, oleic acid, lanolin alcohol and white petrolatum.

Store at controlled room temperature, 20° to 25°C (68° to 77°F) (see USP). Keep tightly closed.

Manufactured for Dermik Laboratories, Inc.
A Pierre-Fabre Rorer Company, Collingdale, PA, USA 19023
By Pharmaceutical Operations, Kalamazoo, MI, USA 49001

30 Gram Carton
Code 817 484 000

#35107-3900

(diflorsone diacetate ointment 0.05%)
PSORCON® emollient ointment
(diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

DIRECTIONS AND INDICATIONS: For complete product information, see package insert. For external use only. Not for opthalmic use. Keep out of the reach of children. Keep tightly closed.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypolyene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

Manufactured for
Dermik Laboratories, Inc.
A Rhône-Poulenco Rorer Company
Collegeville, PA, USA 18036
By Pharmacia & Upjohn Company
Kalamazoo, MI, USA 49001

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

Exp. date and Control No. on crimp
TM-717E
FOR COMPLETE PRODUCT INFORMATION SEE PACKAGE INSERT.

AVERAGE DOSAGE AND INDICATIONS: See package insert. Literature available to physicians on request. For external use only. Not for ophthalmic use. Keep out of the reach of children.

817 483 000

NET WT 60 GRAMS  TOPICAL  NDC 0066-0275-60

PSORCON® emollient ointment
(diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-sisaryl ether, stearic acid, lanolin alcohol and white petrolatum.

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

Manufactured for Dermik Laboratories, Inc.,
A Rhône-Poulenc Rorer Company, Collegeville, PA, USA 19426
By Pfizer & Upjohn Company, Kalamazoo, MI, USA 49001

Keep tightly closed.

817 483 000

60 Gram Carton
Code 817 483 000

NDA 17-94
NDA 17-994

diflorasone diacetate ointment 0.05%)

3.5 Gram Tube
Code 817 460 000